Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.
Marlies AntlangerOliver DomenigChristopher C KalteneckerJohannes J KovarikVincent RathkolbMartin M MüllerElisabeth SchwaigerManfred HeckingMarko PoglitschMarcus D SäemannChantal KopeckyPublished in: Diabetes, obesity & metabolism (2022)
A distinct RAS modulation by SGLT-2i occurs in diabetic kidney disease reflected by enhancement of the beneficial angiotensin-(1-7) providing a molecular background for this renoprotective therapeutic approach.